Mixtard 30 Penfill (Insulin Human)

Insulin Human, the active ingredient in Mixtard 30 Penfill, is an insulin presented as a 100 U/mL premixed solution for subcutaneous use. It replaces deficient endogenous insulin and helps regulate blood glucose in patients with type 1 and type 2 diabetes mellitus, providing both basal and prandial coverage.

GNH USA supplies Mixtard 30 Penfill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, regulatory compliance and reliable cold‑chain logistics for this biologic product.

Mixtard 30 Penfill is a premixed insulin used to manage diabetes mellitus, a disorder of glucose metabolism.

- Type 1 diabetes mellitus: provides basal and rapid‑acting insulin components to achieve overall glycaemic control and reduce fasting and post‑prandial glucose excursions. - Type 2 diabetes mellitus: combines basal and short‑acting insulin to lower both fasting and mealtime blood glucose, supporting patients who need insulin in addition to oral agents.

The most frequently reported reactions to Mixtard 30 Penfill involve glucose regulation and injection site responses.

Common Side Effects: - Hypoglycemia: low blood glucose episodes, especially if meals are missed or dose is excessive. - Weight gain: modest increase in body weight associated with improved glycaemic control. - Injection site pain or erythema: mild discomfort or redness at the injection site. - Lipodystrophy: localized thickening or loss of subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycemia: profound low glucose requiring assistance. - Anaphylactic reaction: rare systemic allergic response with hives, swelling or respiratory distress. - Edema or heart failure exacerbation: fluid retention that may worsen cardiac conditions.

When using Mixtard 30 Penfill, several precautions should be observed to ensure safety and effectiveness. - Blood glucose monitoring: check levels regularly to adjust dose and avoid hypoglycemia. - Dose adjustment during illness: increase insulin requirements may occur with infection or stress. - Concomitant beta‑blockers: may mask hypoglycemia symptoms, requiring closer monitoring. - Renal or hepatic impairment: use caution as insulin clearance may be reduced. - Pregnancy and lactation: classified as Category B; benefits should outweigh potential risks and dosing is individualized. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the pen.

Mixtard 30 Penfill can interact with other medicines, altering its glucose‑lowering effect or increasing adverse reactions.

Major Interactions (Avoid): - Sulfonylureas and meglitinides: additive hypoglycaemic effect, may cause severe low blood glucose. - Beta‑blockers: can conceal hypoglycaemia signs, requiring vigilant monitoring.

Moderate Interactions (Monitor Closely): - Corticosteroids: raise blood glucose, often necessitating higher insulin doses. - Thiazide diuretics: may increase glucose levels modestly. - ACE inhibitors and ARBs: can enhance insulin sensitivity, potentially leading to hypoglycaemia. - Oral contraceptives: may slightly affect insulin requirements.